Lumican - Derived Peptides Inhibit Melanoma Cell Growth and Migration

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Pietraszek, Katarzyna ^a   Brézillon, Stéphane ^a   Perreau, Corinne ^a   Malicka Błaszkiewicz, Maria ^b   Maquart, François Xavier ^a,c   Wegrowski, Yanusz ^a  

^a UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^b UNIVERSITY OF WROC AW   (Poland)

^c REIMS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FOCAL ADHESION KINASE; LEUCYLPROPYLSERYLVALYLSERYLISOLEUCYLLEUCYLGLUTAMYLLYSYLLEUCYLTYROSYLASPARAGINYLASPARAGINYLLEUCYLSERYLLYSYLASPARTIC ACID; LUMCORIN; LUMICAN; MATRIX METALLOPROTEINASE 14; PROPYLHISTIDINYLLEUCYLARGINYLGLUTAMYLLEUCYLHISTIDINYLLEUCYLASPARTYLASPARAGINYLASPARAGINYLLYSYLLEUCYLTHREONYLARGINYLVALYLPROLINE; SERYLLEUCYLGLUTAMYLLEUCYLASPARTYLLEUCYLASPARAGINYLLYSYLTYROSYLLYSINE; SERYLSERYLLEUCYLLEUCYLGLUTAMYLLEUCYLASPARTYLLEUCYLSERYLTYROSYLASPARAGINYLGLUTAMINYLLEUCYLGLUTAMINYLLYSYLISOLEUCYLPROLINE; TYROSINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL MOTILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MELANOMA CELL; MELANOMA METASTASIS; MIGRATION INHIBITION; MOUSE; NONHUMAN; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; SEQUENCE ANALYSIS;

CELL MOVEMENT; CELL PROLIFERATION; CHONDROITIN SULFATE PROTEOGLYCANS; ENZYME ACTIVATION; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KERATAN SULFATE; MATRIX METALLOPROTEINASE 14; MELANOMA; MELANOMA, EXPERIMENTAL; PEPTIDE FRAGMENTS; PEPTIDES; PHOSPHORYLATION;

EID: 84884834190     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076232     Document Type: Article

References (36)

1. Bogenrieder T, Herlyn M, (2003) Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 22: 6524-6536. doi:10.1038/sj.onc.1206757. PubMed: 14528277.
2. Westermarck J, Kähäri VM, (1999) Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 13: 781-792. PubMed: 10224222.
3. Leeman MF, Curran S, Murray GI, (2003) New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. J Pathol 201: 528-534. doi:10.1002/path.1466. PubMed: 14648655.
4. Hofmann UB, Westphal JR, van Muijen GN, Ruiter DJ, (2000) Matrix metalloproteinases in human melanoma. J Invest Dermatol 115: 337-344. doi:10.1046/j.1523-1747.2000.00068.x. PubMed: 10951266.
5. Artym VV, Zhang Y, Seillier-Moiseiwitsch F, Yamada KM, Mueller SC, (2006) Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function. Cancer Res 66: 3034-3043. doi:10.1158/0008-5472.CAN-05-2177. PubMed: 16540652.
6. Iida J, Wilhelmson KL, Price MA, Wilson CM, Pei D, et al. (2004) Membrane type-1 matrix metalloproteinase promotes human melanoma invasion and growth. J Invest Dermatol 122: 167-176. doi:10.1046/j.0022-202X.2003.22114.x. PubMed: 14962105.
7. Nagase H, (1998) Cell surface activation of progelatinase A (proMMP-2) and cell migration. Cell Res 8: 179-186. doi:10.1038/cr.1998.18. PubMed: 9791731.
8. Järveläinen H, Sainio A, Koulu M, Wight TN, Penttinen R, (2009) Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol Rev 61: 198-223. doi:10.1124/pr.109.001289. PubMed: 19549927.
9. Johnson JM, Young TL, Rada JA, (2006) Small leucine rich repeat proteoglycans (SLRPs) in the human sclera: identification of abundant levels of PRELP. Mol Vis 12: 1057-1066. PubMed: 17093390.
10. Chakravarti S, Stallings RL, SundarRaj N, Cornuet PK, Hassell JR, (1995) Primary structure of human lumican (keratan sulfate proteoglycan) and localization of the gene (LUM) to chromosome 12q21.3-q22. Genomics 27: 481-488. doi:10.1006/geno.1995.1080. PubMed: 7558030.
11. Kajava AV, (1998) Structural diversity of leucine-rich repeat proteins. J Mol Biol 277: 519-527. doi:10.1006/jmbi.1998.1643. PubMed: 9533877.
12. Kalamajski S, Oldberg A, (2009) Homologous sequence in lumican and fibromodulin leucine-rich repeat 5-7 competes for collagen binding. J Biol Chem 284: 534-539. PubMed: 19008226.
13. Iozzo RV, Schaefer L, (2010) Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. FEBS J 277: 3864-3875. doi:10.1111/j.1742-4658.2010.07797.x. PubMed: 20840584.
14. Vuillermoz B, Khoruzhenko A, D'Onofrio MF, Ramont L, Venteo L, et al. (2004) The small leucine-rich proteoglycan lumican inhibits melanoma progression. Exp Cell Res 296: 294-306. doi:10.1016/j.yexcr.2004.02.005. PubMed: 15149859.
15. Brezillon S, Zeltz C, Schneider L, Terryn C, Vuillermoz B, et al. (2009) Lumican inhibits B16F1 melanoma cell lung metastasis. J Physiol Pharmacol 60 (Suppl 4):: 15-22. PubMed: 20083847.
16. Zeltz C, Brézillon S, Käpylä J, Eble JA, Bobichon H, et al. (2010) Lumican inhibits cell migration through alpha2beta1 integrin. Exp Cell Res 316: 2922-2931. doi:10.1016/j.yexcr.2010.08.002. PubMed: 20705068.
17. Radwanska A, Baczynska D, Nowak D, Brézillon S, Popow A, et al. (2008) Lumican affects actin cytoskeletal organization in human melanoma A375 cells. Life Sci 83: 651-660. doi:10.1016/j.lfs.2008.09.008. PubMed: 18848571.
18. Brézillon S, Radwanska A, Zeltz C, Malkowski A, Ploton D, et al. (2009) Lumican core protein inhibits melanoma cell migration via alterations of focal adhesion complexes. Cancer Lett 283: 92-100. doi:10.1016/j.canlet.2009.03.032. PubMed: 19394140.
19. Niewiarowska J, Brézillon S, Sacewicz-Hofman I, Bednarek R, Maquart FX, et al. (2011) Lumican inhibits angiogenesis by interfering with alpha2beta1 receptor activity and downregulating MMP-14 expression. Thromb Res 128: 452-457. doi:10.1016/j.thromres.2011.06.011. PubMed: 21752432.
20. Malinowski M, Pietraszek K, Perreau C, Boguslawski M, Decot V, et al. (2012) Effect of lumican on the migration of human mesenchymal stem cells and endothelial progenitor cells: involvement of matrix metalloproteinase-14. PLOS ONE 7: e50709. doi:10.1371/journal.pone.0050709. PubMed: 23236386.
21. Li Y, Aoki T, Mori Y, Ahmad M, Miyamori H, et al. (2004) Cleavage of lumican by membrane-type matrix metalloproteinase-1 abrogates this proteoglycan-mediated suppression of tumor cell colony formation in soft agar. Cancer Res 64: 7058-7064. doi:10.1158/0008-5472.CAN-04-1038. PubMed: 15466200.
22. Zeltz C, Brézillon S, Perreau C, Ramont L, Maquart FX, et al. (2009) Lumcorin: a leucine-rich repeat 9-derived peptide from human lumican inhibiting melanoma cell migration. FEBS Lett 583: 3027-3032. doi:10.1016/j.febslet.2009.08.012. PubMed: 19686741.
23. Yana I, Weiss SJ, (2000) Regulation of membrane type-1 matrix metalloproteinase activation by proprotein convertases. Mol Cell Biol 11: 2387-2401. doi:10.1091/mbc.11.7.2387. PubMed: 10888676.
24. Pasco S, Ramont L, Maquart FX, Monboisse JC, (2004) Control of melanoma progression by various matrikines from basement membrane macromolecules. Crit Rev Oncol/Hematol 49: 221-233. doi:10.1016/j.critrevonc.2003.09.006. PubMed: 15036262.
25. D'Onofrio MF, Brézillon S, Baranek T, Perreau C, Roughley PJ, et al. (2008) Identification of beta1 integrin as mediator of melanoma cell adhesion to lumican. Biochem Biophys Res Commun 365: 266-272. doi:10.1016/j.bbrc.2007.10.155. PubMed: 17981144.
26. Vivinus-Nebot M, Rousselle P, Breittmayer JP, Cenciarini C, Berrih-Aknin S, et al. (2004) Mature human thymocytes migrate on laminin-5 with activation of metalloproteinase-14 and cleavage of CD44. J Immunol 172: 1397-1406. PubMed: 14734715.
27. Itoh Y, Takamura A, Ito N, Maru Y, Sato H, et al. (2001) Homophilic complex formation of MT1-MMP facilitates proMMP-2 activation on the cell surface and promotes tumor cell invasion. EMBO J 20: 4782-4793. doi:10.1093/emboj/20.17.4782. PubMed: 11532942.
28. Santibáñez JF, Guerrero J, Quintanilla M, Fabra A, Martínez J, (2002) Transforming growth factor-beta1 modulates matrix metalloproteinase-9 production through the Ras/MAPK signaling pathway in transformed keratinocytes. Biochem Biophys Res Commun 296: 267-273. doi:10.1016/S0006-291X(02)00864-1. PubMed: 12163012.
29. Sato H, Takino T, Miyamori H, (2005) Roles of membrane-type matrix metalloproteinase-1 in tumor invasion and metastasis. Cancer Sci 96: 212-217. doi:10.1111/j.1349-7006.2005.00039.x. PubMed: 15819718.
30. Takino T, Miyamori H, Watanabe Y, Yoshioka K, Seiki M, et al. (2004) Membrane type 1 matrix metalloproteinase regulates collagen-dependent mitogen-activated protein/extracellular signal-related kinase activation and cell migration. Cancer Res 64: 1044-1049. doi:10.1158/0008-5472.CAN-03-1843. PubMed: 14871836.
31. Baumann P, Zigrino P, Mauch C, Breitkreutz D, Nischt R, (2000) Membrane-type 1 matrix metalloproteinase-mediated progelatinase A activation in non-tumorigenic and tumorigenic human keratinocytes. Br J Cancer 83: 1387-1393. doi:10.1054/bjoc.2000.1454. PubMed: 11044366.
32. Sulochana KN, Fan H, Jois S, Subramanian V, Sun F, et al. (2005) Peptides derived from human decorin leucine-rich repeat 5 inhibit angiogenesis. J Biol Chem 280: 27935-27948. doi:10.1074/jbc.M414320200. PubMed: 15923192.
33. Han J, Ohno N, Pasco S, Monboisse JC, Borel JP, et al. (1997) A cell binding domain from the alpha3 chain of type IV collagen inhibits proliferation of melanoma cells. J Biol Chem 272: 20395-20401. doi:10.1074/jbc.272.33.20395. PubMed: 9252346.
34. Pasco S, Han J, Gillery P, Bellon G, Maquart FX, et al. (2000) A specific sequence of the noncollagenous domain of the alpha3(IV) chain of type IV collagen inhibits expression and activation of matrix metalloproteinases by tumor cells. Cancer Res 60: 467-473. PubMed: 10667602.
35. Brassart-Pasco S, Sénéchal K, Thevenard J, Ramont L, Devy J, et al. (2012) Tetrastatin, the NC1 domain of the alpha4(IV) collagen chain: a novel potent anti-tumor matrikine. PLOS ONE 7: e29587. doi:10.1371/journal.pone.0029587. PubMed: 22539938.
36. Yi M, Ruoslahti E, (2001) A fibronectin fragment inhibits tumor growth, angiogenesis, and metastasis. Proc Natl Acad Sci U S A 98: 620-624. doi:10.1073/pnas.98.2.620. PubMed: 11209058.